Bevacizumab biosimilar (Biocon/Mylan)

贝伐珠单抗生物类似药（Biocon/Mylan）

Report date: 2024/02/27 11:49:05

Base Information

Drug NameBevacizumab biosimilar (Biocon/Mylan)
Drug Alias Name贝伐单抗生物仿制药（Biocon/Mylan）贝伐珠单抗生物仿制药（Biocon/Mylan）贝伐赛珠单抗生物仿制药（Biocon/Mylan）贝伐人源化单抗生物仿制药（Biocon/Mylan）KRABEVA +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[11] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[11] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2017/11/27
Country/TerritoryBosnia and HerzegovinaBulgariaUnited States +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiocon Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMylan Pharmaceuticals Private LtdBiocon Biologics IncBiosimilar Collaborations Ireland Ltd
Inactive CompaniesMylan Pharmaceuticals IncMylan IncMylan Gmbh
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksWikipediaDrugBankKEGG